BEGIN:VCALENDAR VERSION:2.0 PRODID:-//wp-events-plugin.com//7.2.3.1//EN TZID:America/Phoenix X-WR-TIMEZONE:America/Phoenix BEGIN:VEVENT UID:1578@azbio.org DTSTART;TZID=America/Phoenix:20211019T080000 DTEND;TZID=America/Phoenix:20211019T090000 DTSTAMP:20211001T225635Z URL:https://www.azbio.org/events/health-economics-part-2-calculating-your- products-impact-workshop SUMMARY:AZBioPEERS: Health Economics Part 2: Calculating Your Product’s I mpact - - 19 Oct 21 08:00 DESCRIPTION:\nHealth Economics Part 2: Calculating Your Product’s Impact Workshop\nTuesday October 19th\, 2021   08:00 – 09:00 AM\n\nFeatured Sp eakers:\n\n Ivo Abraham\, PhD\, RN - Professor of Pharmacy Practice and Science\, University of Arizona College of Pharmacy\n\nSession Lead: Joa n Koerber-Walker\n\nWhether it is a new drug\, a new diagnostic\, or anoth er new health technology\, payers and providers will want to know what the impact on their budgets will be if they cover (payers) or purchase (provi ders) the new technology.\n\nPlease join us for a brief intro to Budget Im pact Analysis (BIA) and a real time Case Study of how to calculate your pr oduct's impact and determine what payers will pay for it.\nREGISTER\nAbout Our Speaker:\n\nIvo Abraham\, PhD\, RN\n\n\n\n\n\nProfessor\, Pharmacy Pr actice and Science - University of Arizona College of Pharmacy\n\n\n\n\n\ n\nIvo Abraham is a professor (part-time) in the Department of Pharmacy Pr actice. He has also served on the faculty of Case Western Reserve Universi ty (Cleveland\, Ohio)\, University of Virginia (Charlottesville\, Va.)\, a nd (part-time) Katholieke Universiteit Leuven (Leuven\, Belgium)\; and as visiting professor at Universiteit Maastricht (Maastricht\, The Netherland s)\, University of Florida (Gainesville\, Fla.)\, Rijksuniversiteit Gronin gen (Groningen\, The Netherlands)\, University of Pennsylvania (Philadelph ia\, Penn.)\, and Chang Gung University (Kwei-Shan Tao-Yuan\, Taiwan).  H e has lectured\, consulted\, and conducted research throughout the America s\, Europe\, the Asia-Pacific region\, and Africa. Being part-time\, he di vides his time between the University of Arizona and Matrix45\, a biopharm aceutical research and consulting company\, where he serves as chief scien tist.\n\nFor the past decade or so\, Dr. Abraham’s research has focused mainly on clinical outcomes and effectiveness research\, in particular how variability in (drug-centric) treatment regimens is associated with varia bility in patient outcomes. However\, instead of merely evaluating effecti veness (does the treatment work?)\, the work of his research group address es the equally important questions of when does the treatment work (and wh en not)\, what influences whether the treatment works\, why does the treat ment work in some patients but not in others\, why does the treatment work with some clinicians but not with others\, why is the treatment tolerated by some patients but not by others\, and how much of patient outcomes is related to patient vs. clinician or treatment center?  In this process\, his group uses a comprehensive framework of treatment patterns and outcome s assessment\, vulnerability profiling\, hierarchical modeling\, (non-)res ponder analysis\, and pharmacovigilance and drawing methodologies and stat istical models from other disciplines into biomedical research.\n\nMore re cently\, frustrated by the abundance of evidence but clinicians’ persist ent low adoption of evidence-based guidelines\, he and his colleagues star ted examining how practicing in accordance with evidence-based guidelines is directly associated with patient outcomes.\n\nHe has (co-)authored 260+ articles and 60+ chapters\, and has (co-)edited 29 books\, monographs\, a nd journal issues. Since 1984\, his research has been funded by federal fu nding agencies\, foundations\, and corporations.   He has served as appoi nted ad hoc reviewer for the NIH\, the NIMH\, and the AHRQ. He currently s erves as an expert adviser to the Innovative Medicines Initiative\, a joi nt 2 billion euro undertaking of the European Union and the biopharmaceuti cal industry to stimulate innovation in human therapeutics.\n\nHis educati onal and scientific honors and awards include an Invitational research fel lowship from the Japan Society for the Promotion of Science (2007-2008)\, which he conducted at Hyogo University and Aomori University.\n\n\n\n\n\n& nbsp\;\n\n\n\n\n\n\n\n CATEGORIES:webinars END:VEVENT BEGIN:VTIMEZONE TZID:America/Phoenix X-LIC-LOCATION:America/Phoenix BEGIN:STANDARD DTSTART:20201019T080000 TZOFFSETFROM:-0700 TZOFFSETTO:-0700 TZNAME:MST END:STANDARD END:VTIMEZONE END:VCALENDAR